Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zimberelimab + chemotherapy
- Development stage
- Unknown
- Lead developer
- Guangzhou Gloria Biosciences
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
**Zimberelimab + chemotherapy** is a combination therapy being investigated primarily for cancer treatment, particularly in advanced gastric and gastroesophageal junction adenocarcinoma with elevated AFP and negative HER2 status. Zimberelimab (GLS-010) is a fully human monoclonal IgG4 antibody directed against the PD-1 receptor, functioning as an immune checkpoint inhibitor to restore T-cell activity and promote anti-tumor immunity. As a combination, it is typically administered with standard chemotherapeutic regimens such as XELOX (oxaliplatin + capecitabine) and is also studied with agents like lenvatinib, a multi-tyrosine kinase inhibitor. The primary mechanism of zimberelimab is blockade of PD-1, preventing its interaction with PD-L1/2, thus reversing T-cell suppression in the tumor microenvironment.
- Brand names
- zimberelimab
- Other names
- zimberelimab + chemotherapyGLS-010 + chemotherapy
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on zimberelimab + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zimberelimab + chemotherapy.